Onkaido Therapeutics was an American biotechnology company based in Cambridge, Massachusetts. It was described as a venture company formed, funded and wholly-owned by Moderna.[1]
History
On January 14, 2014, Moderna announced the creation of Onkaido Therapeutics to focus "exclusively on developing mRNA-based oncology treatments."[2][3]
External links
mRNA-based Oncology Treatments. Onkaido Therapeutics. Retrieved October 3, 2014, from http://archive.today/2014.10.03-114431/http://onkaido.com/about ↩︎
Favorito, M. (2014, January 14). Moderna Launches Onkaido Therapeutics to Focus on the Development of mRNA TherapeuticsTM in Oncology with $20 Million Capital Commitment. Moderna Therapeutics. http://archive.today/2016.11.20-035524/http://www.modernatx.com/news-events/press-releases/moderna-launches-onkaido-therapeutics-focus-development-mrna-therapeuticstm ↩︎
Gormley, B. (2014, January 15). Moderna Launches Cancer Drug Co. Onkaido Therapeutics With $20M Investment. Wall Street Journal. http://archive.today/2023.06.05-073743/https://www.wsj.com/amp/articles/DJFVW00020140114ea1eqwhzn ↩︎
